{"schema_version":"secwatch.filing_event.v1","accession":"0001129928-26-000074","form_type":"8-K","ticker":"ONCY","cik":"0001129928","company_name":"ONCOLYTICS BIOTECH INC","filed_at":"2026-10-20T13:37:52+00:00","discovered_at":"2026-10-20T13:39:00.439743+00:00","generated_at":"2026-10-20T13:39:09.633376+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Oncolytics ESMO abstract details 60-patient REO 033 colorectal study; prior REO 022 showed 17-month PFS vs 6","bullets":["REO 033 randomized, open-label Phase 2 study enrolls 30 patients per arm: pelareorep + FOLFIRI + bevacizumab vs FOLFIRI + bevacizumab in 2L RAS-mutant MSS mCRC.","Primary endpoint is objective response rate; secondary endpoints include OS, PFS, disease control rate, duration of response, safety/tolerability, and biomarker sampling.","Recent FDA interactions enable pivotal Part B expansion of REO 033, potentially supporting accelerated approval based on ORR and full approval based on PFS.","Prior REO 022 in 2L KRAS-mutant MSS mCRC more than doubled ORR, median PFS, OS and DOR versus historical FOLFIRI/bevacizumab; headline cites 17-month PFS vs 6 months.","Abstract 994eTiP e-poster at ESMO Congress 2026; lead investigator Sanjay Goel cited conviction pelareorep can meaningfully impact patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001129928-26-000074","json":"https://secwatch.observer/filing/0001129928-26-000074.json","markdown":"https://secwatch.observer/filing/0001129928-26-000074.md","text":"https://secwatch.observer/filing/0001129928-26-000074.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1129928/000112992826000074/0001129928-26-000074-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1129928/000112992826000074/oncy-20261020.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-20T13:39:09.633376+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}